Physician profile
Suraj Mathial
NPI 1982940268
$2,032.36
in general payments reported to CMS, 2019-2025
13 companies · $64.43 in 2025
The $64.43 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $967 · 2022: $62.36 · 2023: $464 · 2024: $474 · 2025: $64.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.78 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $759.10 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $393.52 | 2021-2023 | Ilumya |
| Abbvie INC. | $353.56 | 2021-2023 | |
| Dermavant Sciences, INC. | $175.64 | 2024 | Vtama |
| Vyne Pharmaceuticals INC. | $78.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $68.61 | 2021 | |
| Pfizer INC. | $51.62 | 2021 | |
| Lilly USA, LLC | $46.38 | 2021 | |
| Amgen INC. | $35.49 | 2021-2025 | Otezla |
| Cipher Pharmaceuticals US LLC | $20.41 | 2025 | Spinosad, Natroba |
| Genzyme Corporation | $17.77 | 2021 | |
| Ucb, INC. | $16.47 | 2021 | |
| Leo Pharma INC. | $14.85 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suraj Mathial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.